Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 2/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.38 |
| ▸ | CPT1A | P50416 | 3/20 | 0.36 |
| ▸ | CPT2 | P23786 | 2/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.35 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4078261 | 1.00 | GRM5 (0.39) | GRM5USP30CPT1ACPT2CHRNB2 | |
| SCHEMBL5631797 | 0.98 | USP30 (0.40) | GRM5USP30CPT1ACPT2CHRNB2 | |
| SCHEMBL5631775 | 0.98 | USP30 (0.40) | GRM5USP30CPT1ACPT2CHRNB2 | |
| SCHEMBL4076468 | 0.91 | GRM5 (0.40) | GRM5CPT1ACPT2CHRNB2CHRNA5 | |
| SCHEMBL4076476 | 0.91 | GRM5 (0.40) | GRM5CPT1ACPT2CHRNB2CHRNA5 | |
| SCHEMBL5628529 | 0.89 | GRM5 (0.43) | GRM5USP30CPT1ACPT2 | |
| SCHEMBL8220849 | 0.89 | CPT1A (0.36) | GRM5USP30CPT1ACPT2 | |
| SCHEMBL4072117 | 0.88 | GRM5 (0.41) | GRM5USP30CHRNB2CHRNA5CHRNA4 | |
| SCHEMBL5633655 | 0.88 | GRM5 (0.41) | GRM5USP30CHRNB2CHRNA5CHRNA4 | |
| SCHEMBL5628465 | 0.85 | CHRNB2 (0.52) | GRM5CHRNB2CHRNA5CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2027090-A2 | MGLUR5 MODULATORS II | AstraZeneca AB (SE) | 2009-02-25 | — | — | EP | claimed |
| WO-2007130821-A2 | MGLUR5 MODULATORS II | ASTRAZENECA AB (SE) | 2007-11-15 | — | — | WO | claimed |
| US-20070259916-A1 | mGluR5 modulators II | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | claimed |
| EP-2672971-A1 | METABOTROPIC GLUTAMATE RECEPTOR GROUP I ANTAGONISTS FOR TREATMENT OF ABNORMAL UNION OF TISSUE | Pharmalundensis AB (SE) | 2013-12-18 | — | — | EP | disclosed |
| WO-2012108831-A1 | METABOTROPIC GLUTAMATE RECEPTOR GROUP I ANTAGONISTS FOR TREATMENT OF ABNORMAL UNION OF TISSUE | REDECO CHEM AB (SE) | 2012-08-16 | — | — | WO | disclosed |
| US-20070259916-A1 | mGluR5 modulators II | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
| US-20070259916-A1 | mGluR5 modulators II | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
| US-20070259916-A1 | mGluR5 modulators II | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259916-A1 | mGluR5 modulators II | GRM5, GRM2, GRIK5 | GRM5 1/4885USP30 3230/4885CPT1A 1642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.